deltatrials
Not Yet Recruiting PHASE2 INTERVENTIONAL 3-arm NCT07416058

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC (PHOENIX)

A Multicenter Study of Iparomlimab and Tuvonralimab (QL1706) Plus Platinum-Based Doublet Chemotherapy and Bevacizumab in PD-L1 ≥50% Non-Squamous Non-Small Cell Lung Cancer With Actionable Genomic Alterations (AGA) Resistant to Prior Targeted Therapy

Sponsor: Guangdong Association of Clinical Trials

Conditions Lung Adenocarcinoma
Interventions QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Updated 1 time since 2026 Last updated: Feb 10, 2026 Started: Jan 31, 2026 Primary completion: Dec 31, 2027 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lung Adenocarcinoma, this trial is actively recruiting participants. The trial is conducted by Guangdong Association of Clinical Trials and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Feb 2026 – present · 5 months · monthly snapshotNot Yet Recruiting

Change History

1 version recorded
Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Guangdong Association of Clinical Trials
  • Qilu Pharmaceutical Co., Ltd.
Data source: Guangdong Association of Clinical Trials

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.